Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer Sanofi partnering with the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and.
E-Mail
Credit: Sanford Burnham Prebys
LA JOLLA, CALIF. - May 19, 2021 - A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease.
The study was published in the journal
Nature Communications.
Nearly 80% of breast tumors are estrogen receptor (ER)-positive. For decades, these tumors have been treated with anti-estrogen (endocrine) therapies to lower estrogen levels and help slow the cancer s growth. About 20% of breast cancers are also HER2-positive at diagnosis, and these tumors tend to be more aggressive and fast-growing, as HER2 is a receptor that when active, promotes the rapid growth of breast cancer cel
Press release content from Business Wire. The AP news staff was not involved in its creation.
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
April 10, 2021 GMT
BOULDER, Colo. (BUSINESS WIRE) Apr 10, 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021.
“We remain committed to understanding how Rubraca may benefit patients with cancer, and the data presented at AACR further enhance our understanding in different patient populations and solid tumor types,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “The Phase 1b RAMP data for the combination of Rubra
Beebe Healthcare announced on March 2 that it was welcoming renowned breast surgeon Dr. Diana Dickson-Witmer, MD, FACS, to Beebe Medical Group. She will begin seeing patients in March.
A board-certified surgeon, Dickson-Witmer joins Beebe with decades of experience and expertise in the field of breast surgery and oncology. She will lead the Beebe Center for Breast Health.
âDiana is a preeminent breast surgeon and has been a central figure in Delaware cancer care for years,â said Dr. David A. Tam, MD, MBA, FACHE, president and CEO of Beebe Healthcare. âBeebe is committed to bringing experts in their field, like Diana, to care for those in Sussex County. She joins Beebe as we continue to âCreate the Next Generation of Care.ââ
Share this article
Share this article
PALM BEACH, Fla., Feb. 23, 2021 /PRNewswire/ In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for applications in immunotherapy. Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries. The increase in investment in adoptive T-cell transfer approaches of disease treatment drives and the increasing number of clinical trials the market. Furthermore, technological advancements i